The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Pharmacodynamic Assays, 2013Measuring LRRK2 Cellular Function in Parkinson’s iPSC-Derived Dopaminergic Neurons
Objective/Rationale:
We aim to develop a time-lapse, imaging, pharmacodynamic assay for measuring LRRK2 cellular function in dopaminergic (DA) neurons derived from human induced... -
Research Grant, 2013Alpha-Synuclein-Expression-Lowering Therapeutics: Initial Pre-Clinical Development
Objective/Rationale:
Increased dosage of the alpha-synuclein gene is linked to Parkinson’s disease (PD). Out of 1,126 FDA-approved compounds and health supplements screened, we identified... -
Rapid Response Innovation Awards, 2013BL-OG: A Novel, Minimally-Invasive and Homeostatic Method for Selective Regulation of Neural Dynamics in the Subthalamic Nucleus
Objective/Rationale:
Altered neural activity in the subthalamic nucleus (STN) is believed to be key to Parkinson’s disease. Accordingly, deep-brain stimulation (DBS) delivered to the STN... -
Biosample and Tissue Resource, 2013Relationship of Vitamin B12 Status and Parkinson's Disease
Objective/Rationale:
Vitamin B12 deficiency can cause a number of neurological symptoms, including instability, neuropathy (which may cause numbness and tingling) and cognitive defects... -
Research Grant, 2013Cutaneous Alpha-Synuclein Deposition — A Biomarker in Parkinson’s Disease
Objective/Rationale:
There is an unmet need for a biomarker in Parkinson’s disease (PD). Accumulating evidence suggests that deposition of alpha-synuclein, the pathological hallmark of PD... -
Therapeutics Development Initiative, 2012Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Model of Parkinson’s Disease
Objective/Rationale:
HE3286 is an anti-inflammatory drug in phase II clinical trials for other diseases that is being evaluated for treatment of Parkinson’s disease (PD). HE3286 taken orally rapidly...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.